XML 135 R91.htm IDEA: XBRL DOCUMENT v3.22.1
Revenues and other income - Additional Information (Details)
€ in Thousands, $ in Millions
1 Months Ended 8 Months Ended 12 Months Ended
Jun. 15, 2021
USD ($)
Jun. 30, 2021
EUR (€)
Jun. 30, 2021
USD ($)
May 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Dec. 31, 2019
EUR (€)
Dec. 31, 2016
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Jun. 30, 2020
EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]                        
Research tax credit utilization period           3 years            
Revenues           € 10 € 50 € 68        
Subsidies           € 126 € 526 € 20        
Percentage of employees' net wages received via subsidies from French government             84.00%          
PGE Loan, BPI France                        
Disclosure of disaggregation of revenue from contracts with customers [line items]                        
Subsidies             € 187          
Notional amount             350         € 5,000
FRANCE                        
Disclosure of disaggregation of revenue from contracts with customers [line items]                        
Subsidies             € 312          
PharmaEngine, NBTWR3                        
Disclosure of disaggregation of revenue from contracts with customers [line items]                        
Upfront payment received | $                     $ 1.0  
Development milestones payments received | $                 $ 1.0 $ 1.0    
PharmaEngine, NBTWR3 | Revenue by type                        
Disclosure of disaggregation of revenue from contracts with customers [line items]                        
Concentration risk percentage           100.00% 100.00% 100.00%        
LianBio, NBTXR3                        
Disclosure of disaggregation of revenue from contracts with customers [line items]                        
Upfront payment received $ 20.0 € 16,500 $ 20.0   $ 20.0              
Minimum threshold to provide additional know-how to third party under collaboration agreement       80.00%                
Milestones achievement, period 18 months                      
LianBio, NBTXR3 | Maximum                        
Disclosure of disaggregation of revenue from contracts with customers [line items]                        
Potential development and commercial milestones payments | $       $ 220.0 $ 220.0